Case Reports
Journal Article
Add like
Add dislike
Add to saved papers

[Mycophenolate mofetil--a new therapeutic agent for chronic autoimmune diseases].

BACKGROUND: Mycophenolate mofetil is an immunosuppressive agent frequently used in regimens to prevent allograft rejection. In this review we focus on mycophenolate mofetil as a potential drug for chronic autoimmune diseases.

MATERIALS AND METHODS: We searched PubMed for relevant literature and present two case histories.

RESULTS AND INTERPRETATION: Treatment with mycophenolate mofetil is best documented in lupus nephritis. In this context, some studies have documented an effect equal to cyclophosphamide for induction treatment, and equal to azathioprine, and better than cyclophosphamide for remission maintenance. Mycophenolate mofetil is today an alternative, although experimental, agent for the treatment of certain autoimmune diseases when conventional drugs have failed or are not tolerated; in the future it may become more widely used for immunosuppression. To establish the role for mycophenolate mofetil, more prospective controlled multicentre studies are warranted.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app